GlassScriptPhysician profile
Sarah E Grimm
NPI 1619163110
$4,638.16
in general payments reported to CMS, 2019-2025
42 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,153 · 2022: $1,217 · 2023: $1,451 · 2024: $475 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.60 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.12 | 2021-2024 | |
| Medtronic, INC. | $525.53 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $389.04 | 2021-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $310.84 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $294.84 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $241.52 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.18 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $180.00 | 2021-2023 | Myrbetriq, Veozah |
| Amgen INC. | $179.67 | 2021-2023 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $139.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.88 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $117.31 | 2021-2023 | |
| Abbott Laboratories | $80.42 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $79.83 | 2021-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $75.25 | 2023 | Spravato |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.